Trial Profile
Efficacy of ranibizumab and pegaptanib on vitreous and plasma homocysteine levels in the treatment of Wet-age-related-macular-degeneration
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 16 May 2016
Price :
$35
*
At a glance
- Drugs Pegaptanib (Primary) ; Ranibizumab (Primary)
- Indications Wet age-related macular degeneration
- Focus Therapeutic Use
- 16 May 2016 New trial record